Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents: A randomized, open-label, crossover, single-centre study in healthy volunteers

Drugs in R and D

Volumn 9, Issue 5, 2008, Pages 335-343

  Padhi, Desmond ^a,c   Salfi, Maggi ^a   Emery, Maurice ^b  

^a AMGEN INC   (United States)

^b AMGEN INC   (United States)

^c NONE   (United States)

Author keywords

Cinacalcet, pharmacokinetics; Cytochrome P450; Drug interactions; Midazolam, pharmacokinetics

Indexed keywords

CINACALCET; CYCLOSPORIN A; CYTOCHROME P450 3A; IMMUNOSUPPRESSIVE AGENT; MIDAZOLAM; RAPAMYCIN; TACROLIMUS;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERCALCEMIA; HYPERHIDROSIS; MALE; MONOTHERAPY; NAUSEA; NORMAL HUMAN; PAPULAR RASH; PARATHYROID CARCINOMA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SINGLE DRUG DOSE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AREA UNDER CURVE; CALCIUM; CALCIUM CHANNEL AGONISTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DATA INTERPRETATION, STATISTICAL; FEMALE; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDAZOLAM; MIDDLE AGED; NAPHTHALENES; NAUSEA; PARESTHESIA; VOMITING; YOUNG ADULT;

EID: 50149118032     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200809050-00004     Document Type: Article

References (37)

1. Salem MM. Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis 1997; 29: 862-5
2. Heaf J, Tvedegaard E, Kanstrup IL, et al. Hyperparathyroidism and long-term bone loss after renal transplantation. Clin Transplant 2003; 17: 268-74
3. Heaf J, Tvedegaard E, Kanstrup IL, et al. Bone loss after renal transplantation: role of hyperparathyroidism, acidosis, cyclosporine and systemic disease. Clin Transplant 2000; 14: 457-63
4. Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J Am Soc Nephrol 2002; 13: 551-8
5. Gwinner W, Suppa S, Mengel M, et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005; 5: 1934-41
6. Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone after renal transplantation. J Nephrol 2004; 17: 190-204
7. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther 2004; 308: 627-35
8. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-80
9. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25
10. Lindberg JS, Culleton B, Wong G, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-7
11. El-Amm JM, Doshi MD, Singh A, et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-9
12. Szwarc I, Argiles A, Garrigue V, et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675-80
13. Serra AL, Schwarz AA, Wick FH, et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1315-9
14. Apostolou T, Damianou L, Kotsiev V, et al. Treatment of severe hypercalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 2006; 65: 374-7
15. Apostolou T, Kollia K, Damianou L, et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006; 38: 3514-6
16. Kruse AE, Eisenberger U, Frey FJ, et al. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-4
17. Leca N, Laftavi M, Gundroo A, et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6: 2391-5
18. Serra AL, Savoca R, Huber AR, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007; 22: 577-83
19. Amgen Inc. Sensipar® (cinacalcet HCl) tablets prescribing information [online]. Available from URL: http://www.sensipar.com/professional/ prescribing_information/prescribing_information.jsp [Accessed 2007 Dec 11]
20. Eichelbaum M, Burk O. CYP3A genetics in drug metabolism. Nat Med 2001; 7: 285-7
21. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-32
22. Arellano C, Philibert C, Vachoux C, et al. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption: in vitro studies with rat everted gut sacs. J Pharm Pharm Sci 2007; 10: 26-36
23. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling; November 1999 [online]. Available from URL: http://www.fda.gov/cder/guidance/index.htm [Accessed 2008 Jul 27]
24. Messa P, Sindici C, Cannella G, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704-13
25. Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325: 544-50
26. Mikuls TR, Julian BA, Bartolucci A, et al. Bone mineral density changes within six months of renal transplantation. Transplantation 2003; 75: 49-54
27. Rubello D, Giannini S, D'Angelo A, et al. Secondary hyperparathyroidism is associated with vitamin D receptor polymorphism and bone density after renal transplantation. Biomed Pharmacother 2005; 59: 402-7
28. Giannini S, D'Angelo A, Carraro G, et al. Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 2001; 56: 353-63
29. Vautour LM, Melton 3rd LJ, Clarke BL, et al. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int 2004; 15: 160-7
30. Suwelack B, Gerhardt U, Witta J, et al. Effect of parathyroid hormone levels on carotid intima-media thickness after renal transplantation. Am J Hypertens 2001; 14: 1012-8
31. Palmer S, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev 2005; (2): CD005015
32. Evenepoel P, Claes K, Kuypers D, et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005; 20: 1714-20
33. Harris RZ, Salfi M, Sullivan JT, et al. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet 2007; 46: 495-501
34. Padhi D, Harris RZ, Salfi M, et al. No effect of renal function or dialysis on pharmacokinetics of cinacalcet (Sensipar®/Mimpara). Clin Pharmacokinet 2005; 44: 509-16
35. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007; 2: 374-84
36. Falck P, Vethe NT, Asberg A, et al. Cinacalcet's effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008; 23: 1048-53
37. Kruse AE, Eisenberger U, Frey FJ, et al. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2007; 22: 2362-5